Castration-resistant prostate cancer: AUA Guideline

Area of Science:

• Oncology
• Urology

Background:

• Castration-resistant prostate cancer (CRPC) presents complex management challenges due to numerous therapeutic options.
• Clinical decision-making is further complicated by the rapid evolution of treatment strategies and FDA-approved agents.

Purpose of the Study:

• To establish a rational basis for managing patients with castration-resistant prostate cancer.
• To provide evidence-based guidance for clinicians treating advanced prostate cancer.

Main Methods:

• A systematic literature review and meta-analysis of 303 English-language, peer-reviewed articles published from 1996-2013.
• Inclusion of clinical principles and expert opinions for statements lacking sufficient evidence.
• Development of six index patient cases to represent common clinical scenarios.

Main Results:

• Guideline statements address diverse treatment modalities including observation, hormonal therapies, chemotherapy, immunotherapy, and palliative care.
• Recommendations cover the appropriate use of androgen-deprivation therapy, antiandrogen therapy, and androgen synthesis inhibitors.
• Guidance is provided for radionuclide therapy, systemic chemotherapy, palliative care, and bone health management in CRPC patients.

Conclusions:

• The increasing number of therapeutic agents for metastatic CRPC necessitates complex treatment sequencing.
• Guidelines should be used alongside recent literature reviews and patient-specific treatment goals.
• Patient preferences and personal goals are paramount in selecting management strategies for CRPC.